Atom Investors’s VistaGen Therapeutics VTGN Stock Holding History

Atom Investors’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-639	Closed	-$41K	–	341
2021 Q1	$41K	Buy	+639	New	+$42.7K	0.01%	235

Other funds holding VTGN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atom Investors's VTGN Position: Q2 2021 in Review

Atom Investors sold out of VistaGen Therapeutics (VTGN) in Q2 2021, closing a stake of 639 shares — an estimated $41K sold.

Atom Investors first reported a position in VTGN in Q1 2021 and held it in 1 quarter. The position peaked at $41K in Q1 2021. 101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

Atom Investors reported no remaining VistaGen Therapeutics position as of Q2 2021 after selling out during the quarter.
Atom Investors sold 639 VistaGen Therapeutics shares in Q2 2021, an estimated $41K.
Atom Investors first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 1 quarter.
Atom Investors's VistaGen Therapeutics position peaked at $41K in Q1 2021.
101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on Atom Investors's 13F filing for Q2 2021, filed 16 Aug 2021.